Propanc Health Group Corporation — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2013, with comparison to fiscal 2012. The filing is an annual report, not a report for 2012 Q4. The company describes itself as a development-stage healthcare company focused on investigational cancer treatments.
Business context and key metrics
Propanc is pre-revenue and is developing PRP and PRP-DCM, experimental proenzyme formulations intended initially for patients with advanced solid tumors, particularly colorectal and pancreatic cancers. The filing reports no products available for sale and no clinical trials underway.
| Metric | FY2013 | FY2012 |
|---|---|---|
| Revenue | $0 | $0 |
| Net loss | $1,442,638 | $11,434,375 |
| Operating cash used | $128,647 | $170,278 |
| Cash at year-end | $0 | $179 |
| Research and development expense | $12,344 | $5,279 |
FY2013 operating expenses were $1,361,900, including administration expense of approximately $1.34 million. No meaningful revenue or profit margins are reported. The lower FY2013 net loss largely reflects the absence of the prior-year non-cash share-based and prepaid-consulting charges; FY2012 included approximately $10.8 million of expense from amortizing shares issued for investor-relations services. FY2013 also included a $108,185 loss on debt settlements and a $60,461 Australian R&D tax-credit benefit.
At June 30, 2013, total assets were $1,747 and current liabilities were $794,223; working capital deficit was $793,014 and stockholders’ deficit was $792,476. Current liabilities included $272,596 accounts payable, $251,439 accrued expenses and payables, $130,689 loans from directors/officer, $57,237 due to directors for expenses, and $32,879 in unrelated-party loans. The director/officer loans and unrelated-party loans were past due and in default; the unrelated-party loans bore 10% interest, and director/officer loans bore prime plus 2% (5.25% at year-end). The filing’s audited cash-flow statement reports financing cash inflows of $128,465, while MD&A reports $128,460.
Changes versus prior year
- Net loss fell by approximately $10.0 million, mainly because FY2012 included unusually large non-cash consulting/share-based charges, rather than because of revenue growth.
- Operating cash use declined by about $42,000, which management attributed to limited cash resources and reduced activity.
- R&D spending increased from $5,279 to $12,344 but remained minimal; management said funding constraints delayed the next development stage.
- Current liabilities rose from $584,187 to $794,223, while cash fell from $179 to zero.
Outlook, risks and unusual items
- Funding and going concern: The auditor’s report raises substantial doubt about the company’s ability to continue as a going concern. Management said available cash and committed funding were insufficient for obligations over the next 12 months and that substantial additional financing is required. The financial statements include no adjustments for the outcome of this uncertainty.
- Development outlook: The company plans to pursue nonclinical work and then Phase I, II and III trials, subject to financing and regulatory requirements. It estimates commercialization could take approximately seven years from commencement of Phase I trials. The filing does not provide a clear funded timetable for starting those trials.
- Evidence limitations: The cited experience in 46 patients was a retrospective review, not a controlled prospective clinical trial; the filing notes incomplete records, no control group, no predefined endpoints and no statistical analysis. Reported potential efficacy and tolerability remain unconfirmed.
- Regulatory and product risks: PRP and PRP-DCM are not approved for marketing. Management must select a development candidate, establish safety and efficacy through required studies and obtain regulatory approvals. The mechanism of action remains incompletely understood, and animal-model results for PRP-DCM were mixed.
- Financing after year-end: On September 30, 2013, the subsidiary issued a $139,683 debenture bearing 12% interest, due December 31, 2015, and warrants for 3,000,000 common shares. The debt included prior loans and accrued interest plus $46,446 of new cash. The lender could convert at $0.0698 per share only upon company default; the company also had an option to convert. The filing reports a warrant-related debt discount.
- Governance and controls: Management concluded disclosure controls and internal control over financial reporting were ineffective, citing no audit committee financial expert and insufficient segregation of duties. The company had no audit committee at filing, and its board was seeking an independent financial expert.
- Other: No litigation was pending or threatened that management expected to have a material effect. The University of Bath commercialization agreement provides for royalties of 2% of net revenues and 5% of licensee payments. No amounts were owed under it at filing.
Important facts for investors to verify
- Cash runway, payment status of overdue/defaulted loans and payables, and the availability and terms of additional financing.
- Progress and funding for nonclinical studies, selection between PRP and PRP-DCM, and any regulatory discussions or clinical-trial start date.
- Whether prospective, controlled clinical evidence supports safety and efficacy; distinguish this from the limited retrospective patient review and laboratory findings.
- Patent status and geographic coverage, and the company’s continuing obligations under the University of Bath agreement.
- The FY2013 financing-cash-flow discrepancy ($128,465 in the audited statement versus $128,460 in MD&A), and subsequent debenture, warrant and share issuances and their dilution effects.
- Remediation of the reported material weaknesses and whether independent audit-committee expertise and effective financial-reporting controls are established.